Stomach cancer (gastric cancer) remains one of the most challenging cancers to treat, especially when it is diagnosed at an advanced stage or continues to progress after standard treatments. Although surgery, chemotherapy, targeted therapy, and immunotherapy have improved outcomes for many patients, some individuals eventually face limited treatment options when the disease becomes resistant or returns.
For patients with advanced gastric cancer, especially those with specific molecular characteristics, innovative therapies are opening new possibilities.
Satri-cel, a CLDN18.2-targeted CAR-T cell therapy, is one of the emerging cell therapies being explored for patients with advanced gastric and gastroesophageal junction (GEJ) cancers, got approved in China in June 2026. As world’s first CAR-T cell therapy developed for solid tumors, Satri-cel represents an important step in expanding CAR-T technology beyond blood cancers. For eligible patients, accessing Satri-cel treatment in China may provide an opportunity to explore a personalized immunotherapy approach under the guidance of experienced medical teams.
Gene Medical helps international patients understand this treatment option, connect with qualified specialists in China, and navigate the medical process from initial evaluation to treatment coordination.
What Is Satri-cel CAR-T Cell Therapy?
Satri-cel is an innovative CAR-T cell therapy targeting CLDN18.2, a protein that is highly expressed in many gastric cancers and gastroesophageal junction cancers.
Unlike traditional cancer treatments that directly attack tumor cells through chemotherapy or targeted drugs, CAR-T cell therapy uses a patient’s own immune cells. T cells are collected from the patient, genetically modified in a laboratory to recognize cancer cells expressing the target antigen, expanded, and then returned to the patient to help the immune system identify and attack tumor cells.
Satri-cel is designed to address the challenge of treating solid tumors, where CAR-T cell therapy has historically faced greater difficulties compared with blood cancers.
Who May Consider Satri-cel CAR-T Therapy?
Satri-cel CAR-T cell therapy is developed for patients with CLDN18.2-positive advanced gastric cancer or gastroesophageal junction (GEJ) adenocarcinoma. In general, potential candidates should have:
- CLDN18.2 expression ≥40% of tumor cells with 2+/3+ staining intensity
- HER2-negative status
In addition to these biomarker requirements, doctors will carefully evaluate each patient’s overall medical condition before recommending treatment. The evaluation may include the type and stage of cancer, previous treatments received, response to earlier therapies, current disease status, tumor burden, blood counts, organ function, and overall ability to tolerate CAR-T therapy.
Patients who may be considered are typically those with advanced gastric cancer or GEJ adenocarcinoma whose disease has progressed after standard treatment options and who meet the requirements established by the treating medical team.
Because every patient’s condition is unique, a comprehensive medical review is necessary before determining whether Satri-cel CAR-T therapy may be an appropriate option. The treating specialists will consider all available medical information and recommend the most suitable approach based on the patient’s individual situation.
Learn more about Larry’s journey in exploring Satri-cel treatment.
Potential Benefits of Satri-cel CAR-T Therapy for Stomach Cancer
Satri-cel (CT041) offers a new treatment approach for patients with advanced gastric cancer and gastroesophageal junction (GEJ) cancer, especially those who have limited options after standard therapies.
By targeting CLDN18.2, a marker commonly expressed on many gastric cancer cells, Satri-cel uses a patient’s own modified T cells to recognize and attack tumor cells. This targeted immune-based strategy represents an important advancement in bringing CAR-T technology to solid tumors.
Potential benefits of Satri-cel include:
- A new option for advanced gastric cancer patients after disease progression following standard treatments
- Targeted anti-tumor activity through recognition of CLDN18.2-positive cancer cells
- Personalized cell therapy using the patient’s own immune cells
- A promising approach for solid tumors, an area where CAR-T therapy has faced significant challenges
Treatment suitability and outcomes depend on each patient’s tumor characteristics, previous treatments, and overall health, requiring evaluation by experienced specialists.
Satri-cel CAR-T Treatment Process in China
The treatment journey usually involves several important stages:
1. Medical Record Review
Before traveling to China, patients can provide medical documents for preliminary evaluation, including:
- Pathology reports
- Previous treatment history
- Imaging reports (CT, PET-CT, MRI if available)
- Laboratory results
- Molecular testing information, including CLDN18.2 results if available
The medical team reviews the information to determine whether further evaluation is recommended.
2. Specialist Consultation and Treatment Planning
If the patient appears potentially suitable, our team helps coordinate communication with experienced specialists in China. Doctors will discuss the patient’s condition, additional examinations required, and possible treatment plans.
3. Preparation and CAR-T Manufacturing
If approved for treatment, T cells are collected from the patient and prepared for CAR-T manufacturing according to the medical center’s procedures.
The patient may receive necessary pre-treatment and monitoring before CAR-T cell infusion.
4. CAR-T Infusion and Monitoring
After the manufactured CAR-T cells are ready, they are infused back into the patient. Close monitoring is required after infusion because immune-related reactions can occur.
The medical team will monitor treatment response, manage potential side effects, and provide follow-up care.
Cost of Satri-cel CAR-T Therapy in China
The cost of Satri-cel CAR-T therapy may vary depending on each patient’s medical condition, treatment plan, hospital requirements, and the level of supportive care needed during treatment.
For international patients, the total cost usually includes more than the CAR-T product itself. Expenses may include medical evaluation, specialist consultations, laboratory and imaging tests, T-cell collection, CAR-T manufacturing, infusion, hospitalization, monitoring, and management of potential treatment-related side effects.
As Satri-cel is an advanced cell therapy, the overall cost can be significant. However, treatment costs in China may be more accessible compared with similar advanced cell therapies in some countries.
Before starting treatment, patients will receive a personalized evaluation and cost estimate based on their specific situation. Our team helps international patients understand the expected expenses, coordinate with medical centers, and plan the treatment journey in China.
Why Consider Satri-cel CAR-T Therapy in China?
China has developed a strong ecosystem for cell therapy research and clinical application. For international patients, possible advantages of seeking Satri-cel treatment in China may include:
- Access to innovative CAR-T programs developed in China
- Experienced oncology and cell therapy specialists
- Comprehensive hospital infrastructure for patient monitoring
- Potentially more accessible treatment pathways compared with some regions
Every patient’s situation is different. Treatment decisions should always be made together with qualified physicians after a complete medical evaluation.
Our Support for International Patients Seeking Satri-cel Treatment
Receiving advanced cancer therapy abroad involves more than medical treatment. International patients often need assistance with communication, travel arrangements, hospital coordination, and daily support.
Our patient service team helps international patients throughout the process, including:
- Initial treatment information and case coordination
- Medical record preparation and specialist communication
- Hospital appointment coordination
- Translation and communication support
- Treatment journey planning
- Assistance with accommodation and local arrangements
We help patients navigate the process so they can focus on their treatment and recovery.
Start Your Satri-cel CAR-T Treatment Evaluation
If you or your family member is exploring Satri-cel CAR-T therapy for advanced gastric cancer, the first step is a medical review.
Share your medical history with our team, and we can help you understand whether this treatment option in China may be worth discussing with a specialist.